BioLight Life Sciences cancer diagnostics unit Micromedic Technologies has reached an agreement with Axella Research for the development and commercialization of the CellDetect noninvasive diagnostic test for the monitoring of bladder cancer recurrence.

Axella will contribute more than $1 million in funding and manage clinical trial-related activities, with an eye toward an eventual U.S. regulatory submission. The company also will be entitled to royalties from future U.S.-based sales of the test.

CellDetect enables an accurate diagnosis of cancerous cells based on a unique combination of color differentiation and morphology, BioLight says. It utilizes a proprietary kit containing unique extract and dyes.

The test won CE marking earlier this year for commercialization in Europe. — Michael Cipriano